| dc.contributor.author | Lander, Eric Steven | |
| dc.date.accessioned | 2017-01-18T17:05:13Z | |
| dc.date.available | 2017-01-18T17:05:13Z | |
| dc.date.issued | 2015-07 | |
| dc.identifier.issn | 0028-4793 | |
| dc.identifier.issn | 1533-4406 | |
| dc.identifier.uri | http://hdl.handle.net/1721.1/106527 | |
| dc.description.abstract | Fifty years ago, microbiologists sparked the recombinant-DNA revolution with the discovery that bacteria have innate immune systems based on restriction enzymes. These enzymes bind and cut invading viral genomes at specific short sequences, and scientists rapidly repurposed them to cut and paste DNA in vitro — transforming biologic science and giving rise to the biotechnology industry. | en_US |
| dc.language.iso | en_US | |
| dc.publisher | Massachusetts Medical Society | en_US |
| dc.relation.isversionof | http://dx.doi.org/10.1056/NEJMp1506446 | en_US |
| dc.rights | Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. | en_US |
| dc.source | Massachusetts Medical Society | en_US |
| dc.title | Brave New Genome | en_US |
| dc.type | Article | en_US |
| dc.identifier.citation | Lander, Eric S. “Brave New Genome.” New England Journal of Medicine 373.1 (2015): 5–8. © 2015 Massachusetts Medical Society | en_US |
| dc.contributor.department | Massachusetts Institute of Technology. Department of Biology | en_US |
| dc.contributor.mitauthor | Lander, Eric Steven | |
| dc.relation.journal | New England Journal of Medicine | en_US |
| dc.eprint.version | Final published version | en_US |
| dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
| eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
| dspace.orderedauthors | Lander, Eric S. | en_US |
| dspace.embargo.terms | N | en_US |
| mit.license | PUBLISHER_POLICY | en_US |
| mit.metadata.status | Complete | |
